Antimicrobial Resistance (AMR) is often called the “silent pandemic.” It is not just a future threat; it is happening now, affecting millions of lives globally. While we often think of AMR as a clinical or public health issue, there is a powerful, underutilized weapon in our arsenal: Pharmacovigilance.

Based on the latest insights, here is how the world of drug safety can collaborate with public health to tackle one of humanity’s biggest challenges.

---

The Scale of the Crisis

The numbers are staggering. The World Health Organization (WHO) has declared AMR as one of the top 10 global public health threats facing humanity.

• Direct Impact: 1.27 million deaths per year are directly caused by bacterial AMR.
• Wider Association: 4.95 million deaths are associated with it—more than HIV, TB, and Malaria combined.
• Tragic Reach: 1 in 5 deaths caused by AMR occurs in children under the age of five, often from previously treatable infections.
• Economic Cost: By 2050, AMR could force 28 million people into poverty and add $1 trillion to healthcare costs.

Despite this “Known Global Concern,” there is still a significant lack of awareness, inadequate research, and a shortage of real-world data.

---

The Pharmacovigilance Connection: More Than Just Side Effects

Traditionally, Pharmacovigilance focuses on adverse drug reactions (ADRs). However, the massive safety databases we maintain—like the WHO’s VigiBase and national databases like India’s VigiFlow—are goldmines for AMR surveillance.

How can a safety database detect resistance? It turns out that “resistance” often hides in plain sight within ADR reports. When a drug stops working, it is reported using specific medical terms (MedDRA terminology) that signal potential resistance:

• Drug Ineffective or Therapeutic product ineffective
• Pathogen Resistance or Drug Resistance
• Treatment Failure
• Off-label Use and Prescribing Errors

By analyzing these specific patterns in safety reports, we can identify trends in resistance that clinical trials might miss.

---

The AWaRe Classification: A Tool for Action

To manage antibiotic use effectively, the WHO introduced the AWaRe classification, which Pharmacovigilance professionals can use to categorize and monitor trends.

1. Access: Antibiotics that should be widely available for common infections (e.g., Amoxicillin, Ampicillin).
2. Watch: Antibiotics with higher resistance potential that need to be monitored (e.g., Azithromycin, Ciprofloxacin).
3. Reserve: “Last resort” antibiotics used only when all else fails (e.g., Colistin, Linezolid).

The Data Reality: A sample analysis of VigiBase shows that for “Access” drugs like Amoxicillin, reports of “Drug Ineffective” are high (588 reports), but for “Reserve” drugs like Daptomycin, resistance markers are also appearing, signaling that even our last-line defences are under pressure.

---

The Challenge: Underreporting

The biggest hurdle in using Pharmacovigilance for AMR is Gross Underreporting. In India, for example, with a population of 1.36 billion, the reporting rate is vastly lower than in the US.

• US Reporting Rate: ~7.4 reports per 1,000 people.
• India’s Reality: The reporting is estimated to be underreported by a factor of 200x.

For Pharmacovigilance to truly aid the AMR fight, we need more data. We need healthcare professionals and patients to report not just when a drug causes a rash, but when a drug fails to cure.

The Future: Eco-Pharmacovigilance

The battle against AMR isn’t just in hospitals; it’s in our environment. Eco-Pharmacovigilance is an emerging field looking at how pharmaceutical residues in water and soil contribute to resistance.

• Antibiotics released into the environment (via manufacturing waste, patient excretion, or agriculture) create “hotspots” for bacteria to develop resistance.
• This cycle returns to humans through the water we drink and the food we eat, creating a perfect storm for resistant superbugs.

Conclusion

Pharmacovigilance and AMR teams have operated in silos for too long. By combining the data-mining power of safety databases with public health action, we can spot resistance trends faster and protect the “miracle drugs” that modern medicine relies upon.